Palvella Therapeutics' (PVLA) Buy Rating Reiterated at HC Wainwright

Palvella Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright reiterated its Buy rating on Palvella Therapeutics and maintained a $246 price target, implying about 68.8% upside from the current share price.
  • Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average target of $214.86, though one analyst rates the stock Sell.
  • Palvella reported a quarterly loss of $1.70 per share, which was $0.08 better than analysts expected. Shares opened at $145.77 on Friday.
  • MarketBeat previews the top five stocks to own by December 1st.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $246.00 price target on the stock. HC Wainwright's target price suggests a potential upside of 68.76% from the company's current price.

Other equities research analysts also recently issued research reports about the company. Truist Financial set a $207.00 price target on Palvella Therapeutics in a research report on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Leerink Partners initiated coverage on Palvella Therapeutics in a research report on Monday. They set an "outperform" rating and a $228.00 target price on the stock. Canaccord Genuity Group upped their price objective on Palvella Therapeutics from $232.00 to $243.00 and gave the company a "buy" rating in a research note on Monday, November 9th. Finally, Raymond James Financial set a $226.00 target price on Palvella Therapeutics in a report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Palvella Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $214.86.

View Our Latest Research Report on PVLA

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $145.77 on Friday. Palvella Therapeutics has a 52-week low of $72.22 and a 52-week high of $179.95. The company's fifty day moving average is $142.96 and its two-hundred day moving average is $131.29.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.70) earnings per share for the quarter, topping analysts' consensus estimates of ($1.78) by $0.08. Research analysts predict that Palvella Therapeutics will post -6.29 EPS for the current year.

Insider Transactions at Palvella Therapeutics

In related news, Director George M. Jenkins sold 7,174 shares of Palvella Therapeutics stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total value of $935,202.64. Following the completion of the sale, the director owned 139,790 shares in the company, valued at approximately $18,223,024.40. This trade represents a 4.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kathleen Goin sold 4,313 shares of the stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total transaction of $537,313.54. Following the sale, the chief operating officer owned 2,165 shares of the company's stock, valued at approximately $269,715.70. This represents a 66.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,004 shares of company stock worth $9,145,763 in the last 90 days. 17.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently bought and sold shares of the business. First Light Asset Management LLC boosted its stake in Palvella Therapeutics by 38.3% during the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company's stock valued at $122,251,000 after purchasing an additional 271,617 shares during the period. BlackRock Inc. acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter worth approximately $140,343,000. Marshall Wace LLP boosted its position in Palvella Therapeutics by 11,463.8% in the third quarter. Marshall Wace LLP now owns 329,799 shares of the company's stock valued at $45,489,000 after buying an additional 326,947 shares in the last quarter. Siren L.L.C. lifted its stake in Palvella Therapeutics by 243.3% in the first quarter. Siren L.L.C. now owns 257,485 shares of the company's stock valued at $32,096,000 after buying an additional 182,485 shares in the last quarter. Finally, Primecap Management Co. CA acquired a new position in Palvella Therapeutics during the second quarter valued at approximately $39,150,000. Institutional investors and hedge funds own 40.11% of the company's stock.

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company's platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Featured Stories

Analyst Recommendations for Palvella Therapeutics (NASDAQ:PVLA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Palvella Therapeutics Right Now?

Before you consider Palvella Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.

While Palvella Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines